e-learning
resources
Paris 2018
Monday, 17.09.2018
Clinical management of pleural malignancies, including mesothelioma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.
J. Seymour (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom), M. Dobson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom)
Source:
International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Session:
Clinical management of pleural malignancies, including mesothelioma
Session type:
Thematic Poster
Number:
2882
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Seymour (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom), M. Dobson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom). The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.. 2882
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Management of recurrent Malignant Pleural Effusion: what is the best method?
Source: School Course 2014 - Thoracoscopy and Pleural Techniques
Year: 2014
Management of recurrent Malignant Pleural Effusion: what is the best method?
Source: ERS Course 2015
Year: 2015
Diagnostic yield of combined epidemiological and radiological data in Malignant Pleural Mesothelioma: A Pilot Study
Source: International Congress 2019 – Indoor and outdoor air quality considerations
Year: 2019
Malignant pleural mesothelioma: A retrospective analysis of 32 cases
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Does the sonographic presence and severity of pleural fluid septation have an impact on clinical outcomes in pleural infection? - Data from the Pleural Infection Longitudinal Outcome Study (PILOT)
Source: International Congress 2018 – New methods for diagnosing and treating lung diseases
Year: 2018
The Pleural Effusion And Symptom Evaluation (PLEASE) study of breathlessness in patients with a symptomatic pleural effusion
Source: Eur Respir J, 55 (5) 1900980; 10.1183/13993003.00980-2019
Year: 2020
Survival of patients with malignant pleural effusions: a three-year prospective self-experience study
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018
Heterogeneous delivery of definitive interventions in malignant pleural effusions – results from a Danish survey.
Source: International Congress 2019 – Pleural disease: applying the evidence
Year: 2019
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Source: Eur Respir Rev 2016; 25: 472-486
Year: 2016
The role of a pleural service in optimising pleural disease management
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Late Breaking Abstract - Prognostic and therapeutic markers of malignant pleural effusion – The PROMISE study
Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside
Year: 2017
Role of Biomarkers for Predicting suspecting Malignant Mesothelioma in patients with Pleural Effusion presenting to a tertiary care hospital
Source: International Congress 2019 – Pleural disease: applying the evidence
Year: 2019
Pleural mesothelioma: Our experience in 132 cases
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Real life diagnosis in pleural effusion: a retrospective survey
Source: Eur Respir J 2006; 28: Suppl. 50, 580s
Year: 2006
The effect of co-cancer morbidity on mortality in subjects with malignant mesothelioma - a register based study
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Malignant pleural effusion - diagnosis and treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 272s
Year: 2002
Tunneled indwelling pleural catheter (TPC) in recurrent malignant pleural effusions: A retrospective study of 230 patients
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Malignant pleural effusion management: is combining pleurodesis techniques the way forward? Results of the IPC-PLUS trial.
Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept